Background. Rotavirus is the leading cause of severe gastroenteritis in children worldwide. We evaluated the economic burden of rotavirus and the cost-effectiveness of vaccination from the health care perspective. Methods. Estimates were based on existing epidemiological data, cost estimates, vaccine coverage, and efficacy data, as well as hypothetical vaccine prices. Outcome measures included health care and societal costs of rotavirus and benefits and incremental cost-effectiveness ratio of vaccination. Sensitivity analyses evaluated the impact of estimate uncertainty. Results. Treatment costs increased with income level, and health burden decreased; however, burden varied across regions. On the basis of current vaccination coverage and timing, rotavirus vaccination would annually prevent 228,000 deaths, 13.7 million hospital visits, and 8.7 million disability-adjusted life-years, saving $188 million in treatment costs and $243 million in societal costs. At $5 per dose, the incremental cost-effectiveness ratio in low-, lower-middle-, and upper-middle-income countries was $88, $291, and $329 per disability-adjusted life-year averted, respectively, and $3,015, $9,951 and $11,296 per life saved, respectively. Vaccination would prevent 45% of deaths and 58% of associated medical visits and costs. Conclusions. Vaccination is a cost-effective strategy to reduce the health and economic burden of rotavirus. The cost-effectiveness of vaccination depends mostly on vaccine price and reaching children at highest risk ofmortality
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the increased availability of international resources to improve childhood vaccination in developing countries, cost-effectiveness analyses are increasingly used by policy-makers to allocate resources among many competing priority interventions. Economic evaluations of vaccines can assess whether they are cost saving (averted costs are greater than the intervention) and their cost-effectiveness (comparing net costs with the health gains).
In the present study, we examined the economic burden of rotavirus and the cost-effectiveness of vaccination in low-and middle-income countries, which account for the vast majority of the global burden of severe rotavirus gastroenteritis [1] . The current analysis assessed the costs and effects of a rotavirus vaccine, compared with current diarrheal control measures without vaccination.
METHODS

Model overview.
We analyzed the economic burden of rotavirus and the cost-effectiveness of routine rotavirus vaccination of infants in low-and middle-income countries. Countries were placed into the regional groups used by the World Health Organization (WHO; African, American, eastern Mediterranean, European, Southeast Asian, and western Pacific regions) [4] , and each regional group was further divided into 3 income strata (low, lower middle, and upper middle) [5] . The regional income group was the unit of analysis, and a total of 17 regional income groups were assessed. Countries included in this analysis account for ∼99% of the global rotavirus mortality burden [1] and 190% of the global 2004 birth cohort [6] .
A Microsoft Excel-based model was developed to estimate the health care and social costs of rotavirus gastroenteritis and the cost-effectiveness of vaccination, which has been described in detail elsewhere [7] . The model estimates health outcomes (hospitalizations, outpatient visits, and deaths) of rotavirus disease and their associated costs for an annual birth cohort [6] followed up for a 5-year period. It also estimates the disease burden and health care costs averted as the result of vaccination. The principal model inputs include epidemiological information on disease incidence, health care treatment costs, and the effectiveness and cost of vaccination (Tables 1 and 2 ). The primary analysis was conducted from a health care system perspective focusing on direct medical costs from hospitalization and outpatient visits. These include the cost of diagnostic tests, medication, supplies, facilities, and personnel. Secondary analyses of economic burden were conducted from a societal perspective and included transportation costs and productivity losses of caregivers. No economic costs were included for cases resulting in death or for patients not seeking formal medical attention. The health burden of rotavirus was also estimated in terms of disability-adjusted life-years (DALYs), which quantify the years lost because of premature mortality and the years lived with disability [38] . Loss of potential productivity because of mortality was not included in the model. The model also estimated the incremental cost-effectiveness ratio (US$ per DALY averted and US$ per death averted) of rotavirus vaccination. Estimates are expressed in 2007 US dollars, and all future costs and DALY estimates are discounted at a rate of 3%.
Rotavirus-associated hospitalizations, outpatient visits, and mortality. For low-, lower-middle-, and upper-middle-in- 
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For the uncertainty analysis, a triangular distribution with bounds of ‫%05ע‬ was used for cost parameters and of ‫%01ע‬ for mortality. Data are from [8, 36, 37] .
come countries, we estimated rates of rotavirus-associated hospitalization and outpatient visits on the basis of the approach described by Parashar et al [39] . Rotavirus-attributable hospitalizations and outpatient visits were estimated by multiplying the number of diarrhea-related hospitalizations and outpatient visits by the estimated proportion of diarrhea events attributable to rotavirus [39] . Estimates of rates of hospitalization and outpatient visits in upper-middle-income countries were based on pooled results of studies conducted in 6 countries in this income stratum [9] [10] [11] [12] [13] [14] . The rate of outpatient visits was estimated to be 8 times that of hospitalization [8] . Annual rates were converted to 5-year cumulative rates.
Estimates of rotavirus mortality rate for each region-income group were calculated on the basis of the population-weighted mean of country-specific rates estimated by the WHO [1] . Rotavirus-associated hospitalizations and deaths were distributed into the following age categories based on a literature review of the age distribution of rotavirus-associated hospitalizations: 0-2 months, 3-5 months, 6-8 months, 9-11 months, 12-23 months, 24-35 months, 36-47 months, and 48-59 months [10, 11, 14, . The distribution of outpatient visits was assumed to be the same.
The DALY burden from rotavirus mortality was calculated on the basis of the standardized life expectancy at 1 year of age. The DALYs from cases of rotavirus disease resulting in outpatient or hospital visits were calculated on the basis of default disability weights [66] and an estimated illness duration of 6 days [36] . To ensure comparability, DALY calculations included age weights and a discount rate of 3% [67] .
Economic costs associated with rotavirus. The direct medical cost includes the costs of a visit or hospital stay and diagnostic tests and medications. Inpatient and outpatient visit costs were estimated using standardized unit costs from the WHO Choosing Interventions that are Cost Effective (CHOICE) project, which estimates per diem hospitalization costs and outpatient visit costs by geographical region and mortality stratum [36] . The published function was used to estimate country-specific hospital per diem costs for the present study. The mean hospital and outpatient unit cost of each regional income group was calculated by determining a populationweighted mean of the country-specific cost estimates. The mean length of hospital stay was estimated to be 4 days [9, 11, 14, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] . Diagnostic and medication costs were estimated as a proportion of the per diem and per visit costs from studies in losses to care providers were estimated in the same manner. Cost estimates were converted from 2000 international dollars to 2007 US dollars with use of the Consumer Price Index [70], purchasing power parity, and official exchange rates [71] .
Vaccination: effectiveness and costs. The vaccine evaluated was a live attenuated monovalent human rotavirus vaccine administered orally with the first and second doses of diphtheria, tetanus, and pertussis vaccine (DTP) at ∼2 and ∼4 months of age, respectively [34] . To estimate vaccination effectiveness, the model combined information on vaccine coverage, vaccine efficacy, and the relative coverage of children at high risk of infection. Vaccine coverage was based on DTP coverage (doses 1 and 2) for each age category with use of 17 demographic and health surveys conducted in low-and lower-middle-income countries [72] . Demographic and health survey estimates were similar to WHO-United Nations Children's Fund (UNICEF) best estimates for DTP coverage [37] . For the European region, WHO-UNICEF estimates for DTP coverage were used because of limited availability of DHS data, and it was assumed that vaccination occurred at the recommended time. Because few DHS data were available for upper-middle-income countries, vaccine timing and coverage were assumed to be the same as those in lower-middle-income countries.
Several studies suggest that infants who die of diarrhea are less likely to have access to routine vaccinations [62, [73] [74] [75] . The model assumed that children who would die of diarrhea in the absence of rotavirus vaccination have a lower level of vaccination coverage. For the base case, vaccination coverage among children at high risk of infection was assumed to be 90% (range, 50%-100%) that among children at low risk of infection.
Vaccine efficacy against severe rotavirus disease resulting in hospitalization was 85%, based on data from Latin America [33] . This efficacy was also assumed for mortality. Efficacy against outpatient visits was estimated as the mean efficacy reported for severe (85%) [33] and any (70%) [34] rotavirus gastroenteritis. The efficacy of receiving 1 dose was assumed to be 50% of that of a full course.
The cost of vaccination includes administration costs, the price of each dose, and expected losses from waste. Administration costs for the low-and lower-middle-income countries were estimated using the WHO Global Immunization Vision and Strategy costing model [76] . Costs for the upper-middleincome countries were assumed to be twice those for the lowermiddle-income group for each region. Because the current and future price of rotavirus vaccines is currently unknown, the analysis used a price range of $2-$15 per 2-dose course. A 10% vaccine wastage rate was assumed. The cost of adverse events associated with vaccination was not included, because the vaccine has a safety profile equivalent to that of placebo [34] .
Cost-effectiveness. The primary measures of cost-effectiveness in this study are the incremental cost per DALY averted and incremental cost per death averted. The incremental cost is the difference in the costs with and without vaccination (costs of vaccination minus the averted costs from prevented cases). The incremental cost-effectiveness ratio (ICER) is defined as the incremental costs divided by the difference in the DALYs (or deaths) with and without vaccination. Cost-effectiveness was assessed from the health care system perspective for comparability with other published studies. The break-even price, which is the price per vaccine dose at which the costs averted because of vaccination exactly offset the costs of vaccination, was calculated from the health care system and societal perspective.
Uncertainty and sensitivity analyses. One-way sensitivity analyses were completed by varying the individual values for key model inputs among a high, low, and baseline estimate. Variables included hospitalization, outpatient, and mortality rates; vaccine efficacy; relative coverage; and vaccine coverage. The model assumed that rotavirus vaccine coverage would be the same as current coverage and timing for DTP doses 1 and 2. Scenario analyses were conducted to consider on-time coverage, with children vaccinated at the recommended 2 and 4 months of age, and theoretical coverage, assuming both an optimistic level of coverage based on WHO-UNICEF best estimates of coverage [37] and on-time vaccine delivery.
A probabilistic sensitivity analysis was conducted to develop a range of estimates of burden and cost-effectiveness and to identify specific variables that have substantial influence on outcomes and that may merit additional data collection. A Monte Carlo simulation model was developed using distributions for key input variables. Multiple iterations (10,000) generated output distributions and uncertainty limits (5% and 95%) for key variables [77] . Contribution to variance analysis was conducted to determine which input variables contributed the most to the uncertainty in the outputs. Variables used in the model can be found in tables 1-3.
RESULTS
Health and economic burden. Annually, rotavirus accounts for 527,025 deaths and 147 DALYs per 1000 children in all countries included in this analysis (Table 3) . Rotavirus-associated outpatient visits and hospitalizations result in direct medical treatment costs of $325 million ($202 million-$453 million) and total societal costs of $423 million ($262 million-$590 million) each year. In general, there is an inverse relationship between the health burden and economic burden of rotavirus, with health burden concentrated in low-income countries and the economic burden concentrated in uppermiddle-income countries. There is also significant variation in the health and economic burden among countries in different geographic regions that fall into the same income category Vaccine effectiveness and cost-effectiveness. With a national rotavirus vaccination program, an estimated 227,673 lives (209,000-266,000 lives) would be saved in low-and middleincome countries in each annual birth cohort (Table 4 ). In addition to improving health, vaccination would save $188 million ($121 million-$272 million) in treatment costs and $243 million ($157 million-$354 million) in total societal costs.
From the health care system perspective, vaccination would be cost-saving in lower-middle-and upper-middle-income regions for vaccine prices !$0.53 and !$2.00, respectively (break-even price). Vaccination would require a net financial investment at higher prices and at any price in the low-income region. At a vaccine price of $5 per dose, the ICER was $88 ($79-$126), $291 ($242-$402), and $329 ($173-$547) per DALY averted in the low-, lower-middle-, and upper-middleincome groups, respectively. Table 5 shows the differences in benefits and cost-effectiveness of vaccination among regions and income groups. In lowincome countries, vaccination would result in a smaller percentage reduction in rotavirus-associated deaths and medical visits, particularly in Africa and the eastern Mediterranean region (35%). The lower percentage reductions are attributable to lower coverage rates and greater delays in vaccination in these regions. Nevertheless, vaccination would be most costeffective in these same low-income countries because of the higher overall rotavirus-associated mortality rates. Sensitivity and uncertainty. Table 6 shows the results of the 1-way sensitivity analysis for individual variables and their contribution to variance in the probabilistic sensitivity analysis. Results are shown for ICER at $5 per dose for each income level. The contribution to variance shows the proportion of overall uncertainty in cost-effectiveness attributable to the individual variable in the probabilistic model.
In low-and lower-middle-income regions, 3 variables contribute the majority of uncertainty to the estimate of costeffectiveness: vaccine efficacy against rotavirus-associated mortality, rotavirus-associated mortality rate, and relative vaccination coverage among children at the highest risk of rotavirus-associated mortality, compared with children at lower risk. In both income groups, vaccine efficacy contributes over one-half of the overall uncertainty. In the low-income region, economic variables have little effect on overall uncertainty. In lower-middle-and upper-middle-income regions, economic variables, including hospital and outpatient visit costs, contribute more to overall uncertainty regarding cost-effectiveness. Table 7 shows the estimated impact and cost-effectiveness of vaccination for the 3 immunization scenarios examined: current timing, on-time, and theoretical (on-time and increased coverage). On-time immunization would increase the impact of vaccination on mortality, particularly in low-income regions.
In the low-income countries in Africa, it would increase mortality reduction by one-third and reduce the cost-effectiveness ratio by 25%. The theoretical immunization scenario would result in further increases in mortality reduction but no changes in cost-effectiveness.
DISCUSSION
Rotavirus gastroenteritis annually results in 27 million hospital and outpatient visits and 527,000 deaths among children !5 years of age in developing countries, at an estimated treatment cost of $325 million and total societal costs of $423 million. Assuming current vaccination coverage and timing, the integration of a rotavirus vaccine into national vaccination programs could prevent an estimated 227,000 deaths, 13.8 million medical visits, and 7.8 million DALYs, saving $188 million in treatment costs and $243 million in total costs. Vaccination would not be cost-saving at most of the prices considered in this analysis. However, the World Health Report (from 2002) suggests that interventions are very cost-effective if the ICER is less than the country's per capita gross domestic product and are cost-effective if the ICER is !3 times the per capita gross domestic product [78] . With use of these standards, rotavirus vaccination is very cost-effective in all income groups for a range of vaccine prices evaluated in the analysis. The value of rotavirus vaccination as a health investment also depends on the other interventions available for improving child health and the availability of financial resources. On the basis of WHO-CHOICE, point-of-use water disinfection with education is the most cost-effective water and sanitation intervention in most regions, ranging from $161 per DALY in countries in Africa with high mortality to $1092 per DALY in countries in Latin America with low mortality. Introduction of expanded oral rehydration therapy coverage to 50% as a part of supplementation interventions had an ICER of !$25 per DALY in Africa and 1$1200 per DALY in Latin America [79] . These comparisons suggest that rotavirus vaccination could be as cost-effective as other interventions for prevention or treatment of diarrhea, depending on vaccine price. However, differences in the nature of these interventions and the lack of empirical, directly compared cost-effectiveness trials limit the comparability of these results.
Three factors that greatly affected the estimated performance of a rotavirus vaccination program were the timing of vaccine delivery, the overall vaccine coverage, and the relative vaccine coverage among children who die of rotavirus, compared with all children. If a rotavirus vaccine was delivered on time at the age of 2 and 4 months and without the delays assumed in the model, an additional 46,000 rotavirus deaths (total of 274,000 deaths) could be averted. Improving vaccination coverage to the 90th percentile of coverage for each region and income level and optimizing timing of vaccine delivery could prevent an additional 125,978 deaths, compared with current vaccination practices. In low-income countries, vaccination would prevent 41% of rotavirus-related deaths with the current timing and coverage, compared with 67% with optimal levels.
The sensitivity analyses identified several factors that are likely to influence the actual impact and cost-effectiveness of vaccination. In low-income regions, the effectiveness of vaccination will be affected by the efficacy of vaccination in those settings and the ability of vaccination to reach children at high risk of infection on time. Several studies have identified a relationship between immunization status and mortality, which suggests that infants who have been vaccinated are less likely to die than are infants who are not fully immunized [62, [73] [74] [75] .
If those who die are less likely to have been vaccinated, the effectiveness (and cost-effectiveness) of vaccination will be reduced. Targeted efforts to increase the coverage of children at the greatest risk of mortality could improve the impact of vaccination programs.
Several limitations of this study should be considered in the interpretation of the findings. First, estimates of health burden and the impact of vaccination were based on a limited number of publications that may not be generalizable to all countries within income-region strata. Second, there are few empirical data on resource use and cost for rotavirus gastroenteritis, particularly in developing countries. For this reason, a standardized approach developed by the WHO for its WHO-CHOICE project was used. Additional information on treatment and societal costs may provide additional information on the economic benefits of vaccination and potential cost offsets. Third, vaccine price has a significant influence on the cost-effectiveness of vaccination, but precise information on current and future costs are not available. Additional analyses are needed to explore the effect of likely prices on vaccine introduction and cost-effectiveness. Finally, potential herd immunity of rotavirus vaccination was not factored into our analysis; however, any herd immunity effects of rotavirus vaccination would only improve the overall cost-effectiveness of vaccination.
In conclusion, our findings indicate that vaccination can effectively reduce the tremendous health and economic burden of rotavirus gastroenteritis. Timing of vaccination, vaccination coverage, and the ability of vaccination programs to reach children at risk of death due to rotavirus disease will substantially impact the effectiveness of vaccination. Although rotavirus vaccination is unlikely to be cost-saving from the health care perspective at the prices considered, vaccination is cost-effective across a range of prices using several standards. Compared with other interventions to reduce diarrhea-associated mortality, the benefits of rotavirus vaccination may be achieved quickly because of the ability of the vaccine to be incorporated into existing immunization programs and the short time between vaccination and averted mortality. Although rotavirus vaccination may be considered to be cost-effective, it will require an investment of resources to procure and deliver the vaccine, the magnitude of which is determined by vaccine price. Although some of these costs will be defrayed by averted medical costs, additional national or international resources will likely be needed to bring vaccines to children in the poorest countries who need them the most. In the short term, external resources may be available from international donors, such as funding from the GAVI Alliance for eligible low-income countries; however, countries will need to identify internal resources for rotavirus vaccination program sustainability.
